Efficacy and safety of a fixed-dose combination of lercanidipine and enalapril in daily practice. A comparison of office, self-measured and ambulatory blood pressure

Expert Opinion on Pharmacotherapy

Volumn 12, Issue 18, 2011, Pages 2771-2779

  Scholze, Jürgen ^a   Bramlage, Peter ^b   Trenkwalder, Peter ^c   Kreutz, Reinhold ^a  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^b Institut für Kardiovaskuläre Pharmakologie und Epidemiologie   (Germany)

^c Medizinische Klinik   (Germany)

Author keywords

Ambulatory blood pressure; Blood pressure variability; Clinical practice; Enalapril; Lercanidipine; Microalbuminuria; Office blood pressure; Smoothness index

Indexed keywords

ENALAPRIL MALEATE; ENALAPRIL MALEATE PLUS LERCANIDIPINE; LERCANIDIPINE; UNCLASSIFIED DRUG;

ADULT; AMBULATORY MONITORING; ARTICLE; BLOOD PRESSURE MEASUREMENT; BLOOD PRESSURE VARIABILITY; CLINICAL PRACTICE; COMPARATIVE STUDY; COUGHING; DIZZINESS; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; ESSENTIAL HYPERTENSION; FEMALE; FLUSHING; FOLLOW UP; GENERAL PRACTITIONER; HEADACHE; HUMAN; INCIDENCE; MAJOR CLINICAL STUDY; MALE; MEDICAL SPECIALIST; MICROALBUMINURIA; MULTICENTER STUDY; NAUSEA; OPEN STUDY; OUTPATIENT CARE; PERIPHERAL EDEMA; PREVALENCE; PULSE PRESSURE; SELF EXAMINATION; SIDE EFFECT;

ANTIHYPERTENSIVE AGENTS; BLOOD PRESSURE; BLOOD PRESSURE MONITORING, AMBULATORY; DIHYDROPYRIDINES; DRUG COMBINATIONS; ENALAPRIL; FEMALE; FOLLOW-UP STUDIES; GERMANY; HUMANS; MALE; PROSPECTIVE STUDIES; QUESTIONNAIRES; TREATMENT OUTCOME;

EID: 81855173445     PISSN: 14656566     EISSN: 17447666     Source Type: Journal    
DOI: 10.1517/14656566.2011.626770     Document Type: Article

References (27)

1. Puig JG, Calvo C, Luurila O, et al. Lercanidipine, enalapril and their combination in the treatment of elderly hypertensive patients: placebo-controlled, randomized, crossover study with four ABPM. J Hum Hypertens 2007;12:917-24
2. Hair PI, Scott LJ, Perry CM. Fixed-dose combination lercanidipine/ enalapril. Drugs 2007;67:95-106.
3. Agrawal R, Marx A, Haller H. Efficacy and safety of lercanidipine versus hydrochlorothiazide as add-on to enalapril in diabetic populations with uncontrolled hypertension. J Hypertens 2006;24:185-92
4. Theobald K, Capan M, Herbold M, et al. Quality assurance in non-interventional studies. Ger Med Sci 2009;7:doc29
5. Concato J, Shah N, Horwitz RI. Randomized, controlled trials, observational studies, and the hierarchy of research designs. N Engl J Med 2000;342:1887-92
6. Steg PG, Lopez-Sendon J, Lopez de Sa E, et al. External validity of clinical trials in acute myocardial infarction. Arch Intern Med 2007;167:68-73
7. Rump LC. Efficacy and tolerability of the fixed lercanidipine-enalapril combination in the treatment of patients with essential hypertension. Arzneimittelforschung 2010;60:124-30
8. Dolan E, Stanton A, Thijs L, et al. Superiority of ambulatory over clinic blood pressure measurement in predicting mortality: the Dublin outcome study. Hypertension 2005;46:156-61
9. Clement DL, De Buyzere ML, De Bacquer DA, et al. Prognostic value of ambulatory blood-pressure recordings in patients with treated hypertension. N Engl J Med 2003;348:2407-15
10. Salles GF, Cardoso CR, Muxfeldt ES. Prognostic influence of office and ambulatory blood pressures in resistant hypertension. Arch Intern Med 2008;168:2340-6
11. Parati G, Omboni S, Rizzoni D, et al. The smoothness index: a new, reproducible and clinically relevant measure of the homogeneity of the blood pressure reduction with treatment for hypertension. J Hypertens 1998;16:1685-91
12. Mena L, Pintos S, Queipo NV, et al. A reliable index for the prognostic significance of blood pressure variability. J Hypertens 2005;23:505-11
13. Mancia G, De Backer G, Dominiczak A, et al. 2007 Guidelines for the Management of Arterial Hypertension: the Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC).J Hypertens 2007;25:1105-87
14. Figueroa A, Baynard T, Fernhall B, et al. Endurance training improves post-exercise cardiac autonomic modulation in obese women with and without type 2 diabetes. Eur J Appl Physiol 2007;100:437-44
15. Eguchi K, Ishikawa J, Hoshide S, et al. Night time blood pressure variability is a strong predictor for cardiovascular events in patients with type 2 diabetes. Am J Hypertens 2009;22:46-51
16. Rizzoni D, Muiesan ML, SalvettiM, et al. The smoothness index, but not the trough-to-peak ratio predicts changes in carotid artery wall thickness during antihypertensive treatment. J Hypertens 2001;19:703-11
17. Schmieder RE, Schrader J, Zidek W, et al. Low-grade albuminuria and cardiovascular risk: what is the evidence? Clin Res Cardiol 2007;96:247-57
18. Dalla Vestra M, Pozza G, Mosca A, et al. Effect of lercanidipine compared with ramipril on albumin excretion rate in hypertensive type 2 diabetic patients with microalbuminuria: DIAL study (diabete, ipertensione, albuminuria, lercanidipina).Diabetes Nutr Metab 2004;17:259-66
19. Barnett AH, Bain SC, Bouter P, et al. Angiotensin-receptor blockade versus converting-enzyme inhibition in type 2 diabetes and nephropathy. N Engl J Med 2004;351:1952-61
20. Parving HH, Lehnert H, Brochner-Mortensen J, et al. The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes. N Engl J Med 2001;345:870-8
21. Luders S, Franz IW, Hilgers KF, et al. Twenty-four hour ambulatory blood pressure monitoring [in German]. Dtsch Med Wochenschr 2005;130:2664-8
22. Beitelshees AL, Gong Y, Bailey KR, et al. Comparison of office, ambulatory, and home blood pressure antihypertensive response to atenolol and hydrochlorthiazide. J Clin Hypertens (Greenwich) 2010;12:14-21
23. Mengden T, Binswanger B, Weisser B, VetterW. An evaluation of self-measured blood pressure in a study with a calcium-channel antagonist versus a beta-blocker. Am J Hypertens 1992;5:154-60
24. Head GA, Mihailidou AS, Duggan KA, et al. Definition of ambulatory blood pressure targets for diagnosis and treatment of hypertension in relation to clinic blood pressure: prospective cohort study. BMJ 2010;340:c1104
25. Leonetti G, Magnani B, Pessina AC, et al. Tolerability of long-term treatment with lercanidipine versus amlodipine and lacidipine in elderly hypertensives. Am J Hypertens 2002;15:932-40
26. Lund-Johansen P, Stranden E, Helberg S, et al. Quantification of leg oedema in postmenopausal hypertensive patients treated with lercanidipine or amlodipine. J Hypertens 2003;21:1003-10
27. Scholze J, Bida M, Hansen A, et al. Initiation of hypertension treatment with a fixed-dose combination or its monocomponents - does it really matter? Int J Clin Pract 2006;60:265-74